A PLACEBO-CONTROLLED PHASE 1 STUDY IN HEALTHY ADULT VOLUNTEERS OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALPN-303, A POTENT DUAL BAFF/APRIL ANTAGONIST, FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

Authors
Category Primary study
JournalANNALS OF THE RHEUMATIC DISEASES
Year 2023
This article has no abstract
Epistemonikos ID: c275f834f5ebba5c2c2a1559e6e1638b73b24ac0
First added on: Dec 07, 2023